• 1
    Cheson BD, Leonard JP. Monoclonal antibody therapy for B-cell non-Hodgkin’s lymphoma. N Engl J Med 2008; 359: 61326.
  • 2
    Boyiadzis M, Foon KA. Approved monoclonal antibodies for cancer therapy. Expert Opin Biol Ther 2008; 8: 11518.
  • 3
    Dalle S, Thieblemont C, Thomas L, Dumontet C. Monoclonal antibodies in clinical oncology. Anticancer Agents Med Chem 2008; 8: 52332.
  • 4
    Mauri D, Polyzos NP, Salanti G, Pavlidis N, Ioannidis JP. Multiple-treatments meta-analysis of chemotherapy and targeted therapies in advanced breast cancer. J Natl Cancer Inst 2008; 100: 178091.
  • 5
    Tassev DV, Cheung NK. Monoclonal antibody therapies for solid tumors. Expert Opin Biol Ther 2009; 9: 34153.
  • 6
    Beckman RA, Weiner LM, Davis HM. Antibody constructs in cancer therapy: protein engineering strategies to improve exposure in solid tumors. Cancer 2007; 109: 1709.
  • 7
    Baker JH, Lindquist KE, Huxham LA, Kyle AH, Sy JT, Minchinton AI. Direct visualization of heterogeneous extravascular distribution of trastuzumab in human epidermal growth factor receptor type 2 overexpressing xenografts. Clin Cancer Res 2008; 14: 21719.
  • 8
    Choi J, Credit K, Henderson K et al. Intraperitoneal immunotherapy for metastatic ovarian carcinoma: resistance of intratumoral collagen to antibody penetration. Clin Cancer Res 2006; 12: 190612.
  • 9
    Du Y, Honeychurch J, Glennie M, Johnson P, Illidge T. Microscopic intratumoral dosimetry of radiolabeled antibodies is a critical determinant of successful radioimmunotherapy in B-cell lymphoma. Cancer Res 2007; 67: 133543.
  • 10
    Fidarova EF, El-Emir E, Boxer GM et al. Microdistribution of targeted, fluorescently labeled anti-carcinoembryonic antigen antibody in metastatic colorectal cancer: implications for radioimmunotherapy. Clin Cancer Res 2008; 14: 263946.
  • 11
    Flessner MF, Choi J, Credit K, Deverkadra R, Henderson K. Resistance of tumor interstitial pressure to the penetration of intraperitoneally delivered antibodies into metastatic ovarian tumors. Clin Cancer Res 2005; 11: 311725.
  • 12
    Juweid M, Neumann R, Paik C et al. Micropharmacology of monoclonal antibodies in solid tumors: direct experimental evidence for a binding site barrier. Cancer Res 1992; 52: 514453.
  • 13
    Saga T, Neumann RD, Heya T et al. Targeting cancer micrometastases with monoclonal antibodies: a binding-site barrier. Proc Natl Acad Sci U S A 1995; 92: 89999003.
  • 14
    El Emir E, Qureshi U, Dearling JL et al. Predicting response to radioimmunotherapy from the tumor microenvironment of colorectal carcinomas. Cancer Res 2007; 67: 11896905.
  • 15
    Flessner MF, Dedrick RL. Monoclonal antibody delivery to intraperitoneal tumors in rats: effects of route of administration and intraperitoneal solution osmolality. Cancer Res 1994; 54: 437684.
  • 16
    Jain RK. Physiological barriers to delivery of monoclonal antibodies and other macromolecules in tumors. Cancer Res 1990; 50: 814s9s.
  • 17
    Aarts F, Bleichrodt RP, Oyen WJ, Boerman OC. Intracavitary radioimmunotherapy to treat solid tumors. Cancer Biother Radiopharm 2008; 23: 92107.
  • 18
    Koppe MJ, Hendriks T, Boerman OC, Oyen WJ, Bleichrodt RP. Radioimmunotherapy is an effective adjuvant treatment after cytoreductive surgery of experimental colonic peritoneal carcinomatosis. J Nucl Med 2006; 47: 186774.
  • 19
    Meredith RF, Buchsbaum DJ, Alvarez RD, LoBuglio AF. Brief overview of preclinical and clinical studies in the development of intraperitoneal radioimmunotherapy for ovarian cancer. Clin Cancer Res 2007; 13: 5643s5s.
  • 20
    Hung MC, Zhang X, Yan DH et al. Aberrant expression of the c-erbB-2/neu protooncogene in ovarian cancer. Cancer Lett 1992; 61: 95103.
  • 21
    Fujimori K, Covell DG, Fletcher JE, Weinstein JN. A modeling analysis of monoclonal antibody percolation through tumors: a binding-site barrier. J Nucl Med 1990; 31: 11918.
  • 22
    Fujimori K, Covell DG, Fletcher JE, Weinstein JN. Modeling analysis of the global and microscopic distribution of immunoglobulin G, F(ab’)2, and Fab in tumors. Cancer Res 1989; 49: 565663.
  • 23
    Koyama Y, Hama Y, Urano Y, Nguyen DM, Choyke PL, Kobayashi H. Spectral fluorescence molecular imaging of lung metastases targeting HER2/neu. Clin Cancer Res 2007; 13: 293645.
  • 24
    McDonald DM, Choyke PL. Imaging of angiogenesis: from microscope to clinic. Nat Med 2003; 9: 71325.
  • 25
    Tanaka T, Furukawa T, Fujieda S, Kasamatsu S, Yonekura Y, Fujibayashi Y. Double-tracer autoradiography with Cu-ATSM/FDG and immunohistochemical interpretation in four different mouse implanted tumor models. Nucl Med Biol 2006; 33: 74350.